FDA Greenlights Cheaper THC Meds: No Safety Scares Here
Published Date: 7/3/2025
Notice
Summary
The FDA says SYNDROS (dronabinol) solution wasn’t pulled from the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they follow the rules. Patients and pharmacies could see more affordable options soon without any safety worries!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Clears Way for SYNDROS Generics
The FDA determined that SYNDROS (dronabinol) solution, 5 mg/mL, was not withdrawn from sale for reasons of safety or effectiveness. Because of that finding, the FDA can approve abbreviated new drug applications (ANDAs) for SYNDROS 5 mg/mL if all other legal and regulatory requirements are met, which could allow generic versions to reach patients and pharmacies.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in